Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sym004 versus futuximab or modotuximab in anti-EGFR-resistant metastatic colorectal carcinoma
2018-000618-39Phase 2Terminated
- Sponsor
- Symphogen
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of futuximab + modotuximab, futuximab and modotuximab in colorectal cancer (CRC) (3 arms), sponsored by Symphogen. Primary endpoint: Percentage change from baseline in sum of target lesion diameters at end of cycle 2. Started Oct 2018; status: terminated.
02
Drugs
futuximab + modotuximabfutuximabmodotuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2018-000618-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000618-39.